SEC Form 5 · accession 0000925421-19-000049
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Dec 31, 2018
Accepted (ET)
Feb 14, 2019 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 16, 2018 | J | 25,074 | $0.00 | A | 4,302,147 | D | |
| Common StockF2 | Jun 18, 2018 | J | 25,074 | $0.00 | A | 4,327,221 | D | |
| Common StockF2 | Jul 16, 2018 | J | 25,074 | $0.00 | A | 4,352,295 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. ("NIBRI") is a limited partner.
- F2The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG.